LivingGLP1
parallel randomized trial

NCT03600480

Investigation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Dosing of NNC0174-0833 in Combination With Semaglutide in Subjects Being Overweight or With Obesity

Design

Randomized
96
Start year
2018
Treatment
20 weeks, follow-up 25 weeks
Countries
Sponsor
Novo Nordisk A/S (industry)
Eligibility
age 18 to 55; BMI 27 to 39.9; men or women not of childbearing potential

Conduct and analysis

Blinding
double blind
Sequence generation
not reported
Allocation concealment
not reported
Outcome adjudication
not reported
Primary estimand
not stated
Analysis population
Missing data
not reported

Arms

ArmTreatmentBackgroundRandomizedAnalyzedCompleted treatment
A1semaglutide and cagrilintide
AM833 0.16 mg plus semaglutide 2.4 mg
lifestyle: not reported
A2semaglutide and cagrilintide
AM833 0.3 mg plus semaglutide 2.4 mg
lifestyle: not reported
A3semaglutide and cagrilintide
AM833 0.6 mg plus semaglutide 2.4 mg
lifestyle: not reported
A4semaglutide and cagrilintide
AM833 1.2 mg plus semaglutide 2.4 mg
lifestyle: not reported
A5Cagrilintide and semaglutide 2.4/2.4 mg subcutaneous once weekly
AM833 2.4 mg plus semaglutide 2.4 mg
lifestyle: not reported
A6semaglutide and cagrilintide
AM833 4.5 mg plus semaglutide 2.4 mg
lifestyle: not reported
A7Semaglutide 2.4 mg subcutaneous once weekly
Pooled placebo plus semaglutide 2.4 mg
lifestyle: not reported
A8Semaglutide 2.4 mg subcutaneous once weekly
Matched placebo plus semaglutide 2.4 mg
lifestyle: not reported

Baseline characteristics

As printed in the trial reports or registry, per arm or for the whole trial.
CharacteristicStatisticAM833 0.16 mg plus semaglutide 2.4 mg
A1
AM833 0.3 mg plus semaglutide 2.4 mg
A2
AM833 0.6 mg plus semaglutide 2.4 mg
A3
AM833 1.2 mg plus semaglutide 2.4 mg
A4
Cagrilintide and semaglutide 2.4/2.4 mg subcutaneous once weekly
A5
AM833 4.5 mg plus semaglutide 2.4 mg
A6
Semaglutide 2.4 mg subcutaneous once weekly
A7
Semaglutide 2.4 mg subcutaneous once weekly
A8
Whole trial
ALL
agemean (years)40.6
bmimean (kg/m2)32.1
other malepercent59
weightmean (kg)95.7

Results

5 adjudicated result lines, grouped by outcome. Open an outcome to see its values.
Percent body weight change (5 lines; O10)
WeekArmStatisticEstimateSE or SD95% CIEvents / NDetail
20A4percent change-15.7 percentnot stated; other; R0012827:Abstract
20A5percent change-17.1 percentnot stated; other; R0012827:Abstract
20A6percent change-15.4 percentnot stated; other; R0012827:Abstract
20A7percent change-9.8 percentnot stated; other; R0012827:Abstract
20A8percent change-8.0 percentnot stated; other; R0012827:Abstract